SCHEMBL1027886

SCHEMBL1027886

N#Cc1ccccc1-c1cccc(OC2CC3CCC(C2)N3)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 17/20 1.00
SLC6A2 P23975 16/20 1.00
KCNH2 Q12809 5/20 1.00
SLC6A3 Q01959 12/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12955592 1.00 SLC6A4 (1.00) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL1028348 0.85 SLC6A4 (1.00) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL12955916 0.85 SLC6A4 (1.00) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL1029502 0.84 SLC6A4 (0.78) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL12955674 0.84 SLC6A4 (0.78) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL1027408 0.81 SLC6A2 (0.74) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL12955956 0.81 SLC6A2 (0.74) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL1029618 0.78 SLC6A4 (1.00) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL1029616 0.78 SLC6A4 (1.00) SLC6A4SLC6A2KCNH2SLC6A3
SCHEMBL1027920 0.77 SLC6A4 (0.66) SLC6A4SLC6A2KCNH2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957493-B1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS ORGANON NV (NL) 2011-01-19 EP claimed
US-7605170-B2 8-azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2009-10-20 US claimed
EP-1957493-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-08-20 EP claimed
US-20070185156-A1 8-Azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2007-08-09 US claimed
WO-2007063071-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-06-07 WO claimed
EP-1957493-B1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS ORGANON NV (NL) 2011-01-19 EP disclosed
US-7605170-B2 8-azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2009-10-20 US disclosed
EP-1957493-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-08-20 EP disclosed
US-20070185156-A1 8-Azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2007-08-09 US disclosed
WO-2007063071-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185156-A1 8-Azabicyclo[3.2.1]octane derivatives SLC22A8, SLCO1B3, SLCO1B1 SLC6A4 903/4885SLC6A2 511/4885KCNH2 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.